secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001937653-25-000026
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks Q1 revenue $27.1M, net loss narrows to $22.6M; cash runway into 2H-2027
--------------------------------------------------------------------------------

- Revenue of $27.1M (vs. $10.0M in Q1 2024); net loss of $22.6M improved from $31.7M.
- Cash resources $321.6M; combined with anticipated milestones expected to fund operations into 2H-2027.
- Partner Jazz received EMA positive opinion for zanidatamab in HER2+ BTC; final decision pending.
- Recognized $14.0M GSK milestone (paid Apr 2025) and $3.1M Daiichi Sankyo milestone; additional milestones remain.
- Appointed Dr. Sabeen Mekan as SVP Clinical Development; six preclinical posters presented at AACR.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000193765325000026/0001937653-25-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000193765325000026/zyme-20250508.htm
  HTML page:      https://secwatch.observer/filing/0001937653-25-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer